Company intelligence
Avalyn Pharma
Revolutionizing respiratory care with every breath
About Avalyn Pharma
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.
Verified activity
Signals from Avalyn Pharma
3 published signals
Research & Knowledge
Avalyn Pharma presented new AP01 modeling data that demonstrated distribution throughout healthy and fibrotic lungs, including delivery to the primary sites of fibrotic remodeling and active disease.
Reported by Avalyn Pharma
Research & Knowledge
Avalyn Pharma shared survey findings from individuals living with idiopathic pulmonary fibrosis (IPF) highlighting patient interest in clinical research and the importance of clear communication around risks and benefits and recognition of logistical barriers.
Reported by Avalyn Pharma
People
Avalyn Pharma extended a heartfelt thank you to interns for the Summer Internship Program coming to a close.
Reported by Avalyn Pharma